Literature DB >> 25956537

The Impact of Endoscopic Inflammation and Mucosal Healing on Health-related Quality of Life in Ulcerative Colitis Patients.

Klaus Theede1, Marianne Kiszka-Kanowitz2, Inge Nordgaard-Lassen2, Anette Mertz Nielsen2.   

Abstract

BACKGROUND: Health-related quality of life [HRQoL] is impaired in ulcerative colitis and is correlated to clinical disease activity. The recent shift towards more objective treatment goals like mucosal healing generates a need for evaluating the association between endoscopic disease activity, mucosal healing and HRQoL.
METHODS: In this cross-sectional study, patients with either active or inactive ulcerative colitis underwent sigmoidoscopy. Clinical disease activity was assessed by the Simple Clinical Colitis Activity Index [SCCAI], endoscopic inflammation by the Mayo Endoscopic Subscore [MES], and HRQoL by the Short Inflammatory Bowel Disease Questionnaire [SIBDQ] and Short Health Scale [SHS].
RESULTS: A total of 110 patients, 71% with active disease, had a median SCCAI score of 3 and a median MES score of 1. Patients in clinical remission had a mean SIBDQ of 60 and SHS of 6. HRQoL decreased significantly with increasing clinical (SIBDQ [χ(2) = 61.8, p < 0.0001] and SHS [χ(2) = 63.4, p < 0.0001]) and endoscopic disease activity (SIBDQ [χ(2) = 33.1, p < 0.0001] and SHS [χ(2) = 40.3, p < 0.0001]). Mucosal healing was associated with a higher HRQoL than active inflammation (59/46, p < 0.0001 [SIBDQ] and 7/20, p < 0.0001 [SHS]). Decreased HRQoL was observed with more extensive disease. Linear regression revealed strong association between SIBDQ and SHS.
CONCLUSIONS: Not only clinical disease activity but also endoscopic inflammation and disease extent were associated with decreased HRQoL. Patients with mucosal healing had significant higher HRQoL, emphasising the importance of this treatment goal. Both SHS and SIBDQ are easy to use and to implement, and were strongly correlated.
Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Inflammatory bowel disease; health-related quality of life; mucosal healing; patient-related outcome; ulcerative colitis

Mesh:

Year:  2015        PMID: 25956537     DOI: 10.1093/ecco-jcc/jjv081

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  15 in total

Review 1.  Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review.

Authors:  Aaron Yarlas; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Alireza Manuchehri; Paul Healey
Journal:  Qual Life Res       Date:  2017-08-28       Impact factor: 4.147

Review 2.  Mucosal healing in inflammatory bowel disease: Expanding horizon.

Authors:  Jimil Shah; Manik Lal Thakur; Usha Dutta
Journal:  Indian J Gastroenterol       Date:  2019-04-29

3.  Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis.

Authors:  Angela C Cheung; Harshna Patel; Javier Meza-Cardona; Maria Cino; Sanjeev Sockalingam; Gideon M Hirschfield
Journal:  Dig Dis Sci       Date:  2016-01-07       Impact factor: 3.199

4.  Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial.

Authors:  Axel Dignass; Robert Schnabel; Jacek Romatowski; Vladimir Pavlenko; Andrey Dorofeyev; Jelena Derova; Laimas Jonaitis; Karin Dilger; Tanju Nacak; Roland Greinwald
Journal:  United European Gastroenterol J       Date:  2017-03-30       Impact factor: 4.623

5.  The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.

Authors:  Aaron Yarlas; Mary Kaye Willian; Arpita Nag
Journal:  Qual Life Res       Date:  2021-03-02       Impact factor: 4.147

6.  Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease.

Authors:  Annika Gauss; Thomas Geiss; Ulf Hinz; Rainer Schaefert; Philipp Zwickel; Anna Zawierucha; Wolfgang Stremmel; Lukas Klute
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 7.  Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.

Authors:  Adrian D Vickers; Claire Ainsworth; Reema Mody; Annika Bergman; Caroline S Ling; Jasmina Medjedovic; Michael Smyth
Journal:  PLoS One       Date:  2016-10-24       Impact factor: 3.240

8.  Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.

Authors:  Aaron Yarlas; Geert D'Haens; Mary Kaye Willian; Megan Teynor
Journal:  Inflamm Bowel Dis       Date:  2018-01-18       Impact factor: 5.325

9.  Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach.

Authors:  Silvio Danese; Rupa Banerjee; Jr Fraser Cummings; Iris Dotan; Paulo G Kotze; Rupert Wing Loong Leong; Kristine Paridaens; Laurent Peyrin-Biroulet; Glyn Scott; Gert Van Assche; Jan Wehkamp; Jesús K Yamamoto-Furusho
Journal:  Intest Res       Date:  2018-10-16

Review 10.  Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab.

Authors:  Jill Mv Petkau; Bertus Eksteen
Journal:  Biologics       Date:  2016-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.